Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Take Five: Ipsen Bags Rights To Day One Brain Cancer Drug

26 Jul 2024

• By Kevin Grogan

David Loew — David Loew • Source: Ipsen

Related Content

Two Down, One To Go: Second Approval Sealed For Ipsen’s Bylvay

14 Jun 2023

Day One Springs Into Commercial Action With Ojemda Approval

24 Apr 2024

Ipsen Doubles Up In ADC Arena With Foreseen Alliance

11 Jul 2024

Ipsen Gets Ahead Of The Qirv in Cholangitis

11 Jun 2024

Ipsen Dealmaking Heats Up With Marengo Cold Tumor Collaboration

10 Jun 2024

Related Companies

Ipsen SA

Day One Biopharmaceuticals, LLC

Novartis AG

Sutro Biopharma, Inc.

Marengo Therapeutics, Inc.

Skyhawk Therapeutics, Inc.

Genfit SA

Additional Topics

Deals Sales & Earnings Commercial Business Strategies M & A Cancer BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.